Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital National Rare Diseases Committee. Expert Consensus on Clobazam in the Treatment of Refractory Epilepsy (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 768-782. DOI: 10.12290/xhyxzz.2022-0421
Citation: Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital National Rare Diseases Committee. Expert Consensus on Clobazam in the Treatment of Refractory Epilepsy (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 768-782. DOI: 10.12290/xhyxzz.2022-0421

Expert Consensus on Clobazam in the Treatment of Refractory Epilepsy (2022)

Funds: 

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-003

More Information
  • Corresponding authors: ZHANG Bo1, 3, E-mail: zhangbopumch@163.com
    ZHANG Shuyang2, 3, E-mail: zhangshuyang103@163.com
    1. Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
    2. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
    3. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • Received Date: August 01, 2022
  • Accepted Date: August 08, 2022
  • Available Online: August 21, 2022
  • Issue Publish Date: September 29, 2022
  • After regular anti-epileptic drug treatment, the symptoms of most patients with epilepsy can be well controlled or relieved, but 30%-40% of patients with epilepsy, after long-term drug treatment, still suffer from repeated seizures and develop refractory epilepsy. Lennox-Gastaut syndrome, Dravet syndrome and epilepsy with myoclonic-atonic seizures are all refractory epilepsy that originate in childhood and seriously threaten the physical and mental health of patients. In 2011, clobazam was approved by the US Food and Drug Administration for the adjunctive treatment of epileptic seizures in patients with Lennox-Gastaut syndrome aged≥2 years. The drug has also been used in the treatment of Dravet syndrome and epilepsy with myoclonic-atonic seizures. Currently, the mechanism of action of clobazam is still unclear, but it may exert pharmacological effects by binding to the benzodiazepine site on the γ-aminobutyric acid A receptor. In vivo, clobazam and N-desmethylclobazam are mainly metabolized by CYP3A4 and CYP2C19, and the interaction with other drugs should require vigilance in clinical application. Meanwhile, attention should also be paid to the blood concentration of N-desmethylclobazam and monitoring of drug-related adverse reactions in CYP2C19 poor metabolizers. To promote further standardization of clinical application of clobazam in our country, and to ensure the effectiveness and safety of clobazam, the Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital and the National Rare Diseases Committee organized experts and scholars in related fields, and after many discussions and revisions, finally formed this consensus for clinical reference.
  • [1]
    Song P, Liu Y, Yu X, et al. Prevalence of epilepsy in China between 1990 and 2015: A systematic review and meta-analysis[J]. J Glob Health, 2017, 7: 020706. DOI: 10.7189/jogh.07.020706
    [2]
    Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis[J]. Epilepsia, 2018, 59: 2179-2193. DOI: 10.1111/epi.14596
    [3]
    Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2010, 51: 1069-1077.
    [4]
    中国抗癫痫协会. 临床诊疗指南: 癫痫病分册[M]. 北京: 人民卫生出版社, 2015.
    [5]
    Ng YT, Collins SD. Clobazam[J]. Neurotherapeutics, 2007, 4: 138-144. DOI: 10.1016/j.nurt.2006.11.002
    [6]
    Nakajima H. A pharmacological profile of clobazam (Mystan), a new antiepileptic drug[J]. Nihon Yakurigaku Zasshi, 2001, 118: 117-122. DOI: 10.1254/fpj.118.117
    [7]
    Humayun MJ, Samanta D, Carson RP. Clobazam[M]. StatPearls. Treasure Island (FL): StatPearls Publishing, 2022.
    [8]
    FDA Approves Onfi. FDA approves onfi for seizures associated with lennox-gastaut syndrome[EB/OL]. (2022-01-02)[2022-08-11]. https://www.drugs.com/newdrugs/fda-approves-onfi-seizuresassociated-lennox-gastaut-syndrome-2921.html.
    [9]
    Scottish Intercollegiate Guidelines Network. Epilepsies in children and young people: investigative procedures and managemen[EB/OL]. (2021-05)[2022-08-11]. https://www.sign.ac.uk/our-guidelines/epilepsies-in-children-and-young-people-investigative-procedures-and-manage-ment/.
    [10]
    Joshi C, Nickels K, Demarest S, et al. Results of an international Delphi consensus in epilepsy with myoclonic atonic seizures/ Doose syndrome[J]. Seizure, 2021, 85: 12-18. DOI: 10.1016/j.seizure.2020.11.017
    [11]
    Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients[J]. Epilepsy Behav, 2020, 110: 107146. DOI: 10.1016/j.yebeh.2020.107146
    [12]
    Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study[J]. Epilepsia, 2013, 54: 1595-1604. DOI: 10.1111/epi.12303
    [13]
    Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome-Comparison with various standard antiepileptic drug regimen[J]. Epilepsy Res, 2015, 109: 81-89. DOI: 10.1016/j.eplepsyres.2014.10.014
    [14]
    Trivisano M, Striano P, Sartorelli J, et al. CHD2 mutations are a rare cause of generalized epilepsy with myoclonic-atonic seizures[J]. Epilepsy Behav, 2015, 51: 53-56. DOI: 10.1016/j.yebeh.2015.06.029
    [15]
    Vlaskamp DR, Rump P, Callenbach PM, et al. Haploinsufficiency of the STX1B gene is associated with myoclonic astatic epilepsy[J]. Eur J Paediatr Neurol, 2016, 20: 489-492. DOI: 10.1016/j.ejpn.2015.12.014
    [16]
    Song L, Liu F, Liu Y, et al. Clonazepam add-on therapy for drug-resistant epilepsy[J]. Cochrane Database Syst Rev, 2020, 4: Cd012253.
    [17]
    国家药品监督管理局. 氯巴占临时进口工作方案[EB/OL]. (2022-06-29)[2022-08-11]. http://www.nhc.gov.cn/yaozs/s7653/202206/be5e83d15642445f89685af454e1557a.shtml.
    [18]
    Centre for Evidence-Based Medicine. Oxford Center for Evidence-Based Medicine: Levels of Evidence(March 2009)[EB/OL]. (2009-03)[2022-08-11]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009.
    [19]
    翟菲菲, 卢强. 氯巴占在癫痫治疗中的研究进展[J]. 癫痫杂志, 2022, 8: 133-137. https://www.cnki.com.cn/Article/CJFDTOTAL-DXZA202202006.htm
    [20]
    Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1, 5-benzodiazepine clobazam[J]. CNS Drugs, 2012, 26: 229-244. DOI: 10.2165/11599020-000000000-00000
    [21]
    Strzelczyk A, Schubert-Bast S. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies[J]. CNS Drugs, 2021, 35: 61-83. DOI: 10.1007/s40263-020-00784-8
    [22]
    Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children[J]. Epilepsia, 1997, 38: 1283-1288. DOI: 10.1111/j.1528-1157.1997.tb00065.x
    [23]
    European Commission. Rare Disease Registries in Europe. September 2020[EB/OL]. (2020-09)[2022-08-11]. https://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf.
    [24]
    National Organization for Rare Disorders. Rare Disease Database[EB/OL]. [2022-08-11]. https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/.
    [25]
    Ostendorf AP, Ng YT. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions[J]. Neuropsychiatr Dis Treat, 2017, 13: 1131-1140. DOI: 10.2147/NDT.S115996
    [26]
    Cross JH, Auvin S, Falip M, et al. Expert Opinion on the Management of Lennox-Gastaut Syndrome: Treatment Algorithms and Practical Considerations[J]. Front Neurol, 2017, 8: 505. DOI: 10.3389/fneur.2017.00505
    [27]
    National Institute for Health and Care Excellence. Clinical Guidelines. Epilepsies: diagnosis and management[M]. London: National Institute for Health and Care Excellence, 2021.
    [28]
    季涛云, 姜玉武, 蒋莉, 等. Lennox-Gastaut综合征诊断治疗的中国专家共识[J]. 癫痫杂志, 2022, 8: 187-195. https://www.cnki.com.cn/Article/CJFDTOTAL-DXZA202203014.htm
    [29]
    Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome[J]. Epilepsia, 2009, 50: 1158-1166. DOI: 10.1111/j.1528-1167.2008.01935.x
    [30]
    Ng YT, Conry JA, Drummond R, et al. Randomized, phase Ⅲ study results of clobazam in Lennox-Gastaut syndrome[J]. Neurology, 2011, 77: 1473-1481. DOI: 10.1212/WNL.0b013e318232de76
    [31]
    Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study[J]. Epilepsy Behav, 2012, 25: 687-694. DOI: 10.1016/j.yebeh.2012.09.039
    [32]
    Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years[J]. Epilepsia, 2014, 55: 558-567. DOI: 10.1111/epi.12561
    [33]
    Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome[J]. Acta Neurol Scand, 2013, 128: 91-99. DOI: 10.1111/ane.12086
    [34]
    Devi N, Madaan P, Ameen R, et al. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis[J]. Seizure, 2022, 99: 164-175. DOI: 10.1016/j.seizure.2022.04.004
    [35]
    Zhang L, Wang J, Wang C. Efficacy and safety of antisei-zure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis[J]. Dev Med Child Neurol, 2022, 64: 305-313. DOI: 10.1111/dmcn.15072
    [36]
    Engel J Jr, International League Against Epilepsy. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology[J]. Epilepsia, 2001, 42: 796-803. DOI: 10.1046/j.1528-1157.2001.10401.x
    [37]
    Sun H, Zhang Y, Liu X, et al. Analysis of SCN1A mutation and parental origin in patients with Dravet syndrome[J]. J Hum Genet, 2010, 55: 421-427. DOI: 10.1038/jhg.2010.39
    [38]
    Connolly MB. Dravet Syndrome: Diagnosis and Long-Term Course[J]. Can J Neurol Sci, 2016, 43: S3-S8.
    [39]
    刘家雯, 操德智. Dravet综合征临床治疗新进展[J]. 中华实用儿科临床杂志, 2018, 33: 1913-1917. DOI: 10.3760/cma.j.issn.2095-428X.2018.24.020
    [40]
    Lagae L. Dravet syndrome[J]. Curr Opin Neurol, 2021, 34: 213-218. DOI: 10.1097/WCO.0000000000000902
    [41]
    Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome)--a nationwide questionnaire survey in Japan[J]. Brain Dev, 2008, 30: 629-635. DOI: 10.1016/j.braindev.2008.03.002
    [42]
    Wirrell EC, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommenda-tions From a North American Consensus Panel[J]. Pediatric Neurol, 2017, 68: 18-34. e3. DOI: 10.1016/j.pediatrneurol.2017.01.025
    [43]
    Cross JH, Caraballo RH, Nabbout R, et al. Dravet syndrome: Treatment options and management of prolonged seizures[J]. Epilepsia, 2019, 60: S39-S48.
    [44]
    Brigo F, Igwe SC, Bragazzi NL. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy[J]. Cochrane Database Syst Rev, 2017, 5: CD010483.
    [45]
    Doose H, Gerken H, Leonhardt R, et al. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation[J]. Neuropadiatrie, 1970, 2: 59-78. DOI: 10.1055/s-0028-1091841
    [46]
    Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress[J]. Dev Med Child Neurol, 2010, 52: 988-993. DOI: 10.1111/j.1469-8749.2010.03744.x
    [47]
    陈娇阳, 张月华. 癫痫伴肌阵挛-失张力发作的分子遗传学研究进展[J]. 中华儿科杂志, 2019, 57: 384-387. DOI: 10.3760/cma.j.issn.0578-1310.2019.05.015
    [48]
    Nickels K, Kossoff EH, Eschbach K, et al. Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort[J]. Epilepsia, 2021, 62: 120-127. DOI: 10.1111/epi.16752
    [49]
    Kilaru S, Bergqvist AGC. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia[J]. Epilepsia, 2007, 48: 1703-1707. DOI: 10.1111/j.1528-1167.2007.01186.x
    [50]
    Stephani U. The natural history of myoclonic astatic epilepsy (Doose syndrome) and Lennox-Gastaut syndrome[J]. Epilepsia, 2006, 47: 53-55. DOI: 10.1111/j.1528-1167.2006.00690.x
    [51]
    McTague A, Cross JH. Treatment of epileptic encephalopathies[J]. CNS Drugs, 2013, 27: 175-184. DOI: 10.1007/s40263-013-0041-6
    [52]
    邓劼, 张月华, 杨志仙, 等. 肌阵挛失张力癫痫48例治疗及预后随访[J]. 中国实用儿科杂志, 2012, 27: 57-61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201201019.htm
    [53]
    Nickels K, Thibert R, Rau S, et al. How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey[J]. Epilepsy Res, 2018, 144: 14-19. DOI: 10.1016/j.eplepsyres.2018.04.010
    [54]
    Ito S, Nagumo K, Nishikawa A, et al. Low-dose phenobarbital for epilepsy with myoclonic absences: A case report[J]. Brain Dev, 2021, 43: 666-668. DOI: 10.1016/j.braindev.2020.12.018
    [55]
    Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet Syndrome[J]. Paediatric Drugs, 2016, 18: 197-208. DOI: 10.1007/s40272-016-0171-7
    [56]
    Anon. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Cloba-zam Cooperative Group[J]. Epilepsia, 1991, 32: 407-416. DOI: 10.1111/j.1528-1157.1991.tb04670.x
    [57]
    Contin M, Sangiorgi S, Riva R, et al. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam[J]. Ther Drug Monit, 2002, 24: 737-741. DOI: 10.1097/00007691-200212000-00009
    [58]
    Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes[J]. Pharmacotherapy, 2012, 32: 340-353. DOI: 10.1002/j.1875-9114.2012.01028.x
    [59]
    Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017[J]. Pharmacopsychiatry, 2018, 51: 9-62. DOI: 10.1055/s-0043-116492
    [60]
    Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans[J]. Br J Clin Pharmacol, 1979, 7: 51S-57S. DOI: 10.1111/j.1365-2125.1979.tb04665.x
    [61]
    Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2008, 49: 1239-1276. DOI: 10.1111/j.1528-1167.2008.01561.x
    [62]
    Guberman A, Couture M, Blaschuk K, et al. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations[J]. Can J Neurol Sci, 1990, 17: 311-316. DOI: 10.1017/S031716710003064X
    [63]
    Aylett SE, Cross H, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy[J]. Dev Med Child Neurol, 2006, 48: 612-615. DOI: 10.1017/S0012162206001289
    [64]
    Montenegro MA, Arif H, Nahm EA, et al. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center[J]. Clin Neuropharmacol, 2008, 31: 333-338. DOI: 10.1097/WNF.0b013e31815cd960
    [65]
    Naccarato M, Yoong D, Kovacs C, et al. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy[J]. Antivir ther, 2012, 17: 589-592. DOI: 10.3851/IMP1953
    [66]
    Parmeggiani A, Posar A, Sangiorgi S, et al. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19[J]. Brain Dev, 2004, 26: 63-66. DOI: 10.1016/S0387-7604(03)00074-3
    [67]
    Pok PR, Mauras M, De Saint Léger MN, et al. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate[J]. Legal Med (Tokyo), 2010, 12: 300-304. DOI: 10.1016/j.legalmed.2010.08.002
    [68]
    Proença P, Teixeira H, Pinheiro J, et al. Forensic intoxication with clobazam: HPLC/DAD/MSD analysis[J]. Forensic Sci Int, 2004, 143: 205-209. DOI: 10.1016/j.forsciint.2004.03.029
    [69]
    Dean L. Clobazam Therapy and CYP2C19 Genotype[M]. US: National Center for Biotechnology Information, 2012.
    [70]
    Johannessen Landmark C, Heger K, Lund C, et al. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome[J]. Ther Drug Monit, 2020, 42: 744-753. DOI: 10.1097/FTD.0000000000000781
    [71]
    Burns ML, Baftiu A, Opdal MS, et al. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability[J]. Ther Drug Monit, 2016, 38: 350-357. DOI: 10.1097/FTD.0000000000000272
    [72]
    De Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies[J]. Thera Drug Monit, 2013, 35: 30-47. DOI: 10.1097/FTD.0b013e31827ada88
    [73]
    Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics[J]. Pharmacol Res, 2016, 106: 72-86. DOI: 10.1016/j.phrs.2016.02.014
    [74]
    Anon. Thioridazine[J]. Tuberculosis (Edinb), 2008, 88: 164-167. DOI: 10.1016/S1472-9792(08)70028-3
    [75]
    Pasupuleti B, Gone V, Baddam R, et al. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study[J]. Curr Drug Metab, 2020, 21: 126-131. DOI: 10.2174/1389200221666200218121050
    [76]
    Monjanel-Mouterde S, Antoni M, Bun H, et al. Pharmacokinetics of a single oral dose of clobazam in patients with liver disease[J]. Pharmacol Toxicol, 1994, 74: 345-350. DOI: 10.1111/j.1600-0773.1994.tb01371.x
    [77]
    Tolbert D, Bekersky I, Chu HM, et al. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokine-tics[J]. J Clin Pharmacol, 2016, 56: 213-222. DOI: 10.1002/jcph.586
    [78]
    Kamitaki BK, Minacapelli CD, Zhang P, et al. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)[J]. Epilepsy Behav, 2021, 117: 107832. DOI: 10.1016/j.yebeh.2021.107832
    [79]
    Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant[J]. Psychiatr Serv, 2002, 53: 39-49. DOI: 10.1176/appi.ps.53.1.39
    [80]
    Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea[J]. PLoS Med, 2022, 19: e1003945. DOI: 10.1371/journal.pmed.1003945
    [81]
    Suresh L, Radfar L. Pregnancy and lactation[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2004, 97: 672-682. DOI: 10.1016/j.tripleo.2004.02.002
    [82]
    Greenblatt DJ, Divoll M, Puri SK, et al. Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation[J]. Clin Pharmacokinet, 1983, 8: 83-94. DOI: 10.2165/00003088-198308010-00005
    [83]
    Greenblatt DJ, Divoll M, Puri SK, et al. Clobazam kinetics in the elderly[J]. Br J Clin Pharmacol, 1981, 12: 631-636. DOI: 10.1111/j.1365-2125.1981.tb01281.x
    [84]
    Tolbert D, Chu HM, Ette EI. Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome[J]. Epilepsy Res, 2019, 157: 106182. DOI: 10.1016/j.eplepsyres.2019.106182
    [85]
    Hahn J, Lee H, Kang HC, et al. Clobazam as an adjunctive treatment for infantile spasms[J]. Epilepsy Behav, 2019, 95: 161-165. DOI: 10.1016/j.yebeh.2019.03.040
    [86]
    Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus[J]. Epilepsia Open, 2018, 3: 323-330. DOI: 10.1002/epi4.12230
    [87]
    Redondo P, Vicente J, España A, et al. Photo-induced toxic epidermal necrolysis caused by clobazam[J]. Br J Dermatol, 1996, 135: 999-1002. DOI: 10.1046/j.1365-2133.1996.d01-1111.x
    [88]
    Yapici AK, Fidanci MK, Kilic S, et al. Stevens-Johnson Syndrome triggered by a combination of clobazam, lamotrig-ine and valproic acid in a 7-year-old child[J]. Ann Burns Fire Disasters, 2014, 27: 121-125.
    [89]
    Caramaschi P, Biasi D, Carletto A, et al. Clobazam-induced systemic lupus erythematosus[J]. Clin Rheumatol, 1995, 14: 116.
    [90]
    [91]
    Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy[J]. Epilepsy Behav, 2017, 76: 24-231. DOI: 10.1016/j.yebeh.2017.08.039
    [92]
    Kalra V, Seth R, Mishra D, et al. Clobazam in refractory childhood epilepsy[J]. Indian J Pediatr, 2010, 77: 263-266. DOI: 10.1007/s12098-010-0035-z
    [93]
    Gedela S, Freedman DA, Gedela S, et al. Safety and Efficacy of Supratherapeutic Doses of Clobazam[J]. J Child Neurol, 2019, 34: 735-738. DOI: 10.1177/0883073819856834
    [94]
    Schmidt D. Clobazam for treatment of intractable epilepsy: a critical assessment[J]. Epilepsia, 1994, 35: S92-S95. DOI: 10.1111/j.1528-1157.1994.tb05979.x
  • Cited by

    Periodical cited type(14)

    1. 王锐园,王宁,刘叶. 麻精药品合理使用制度的优化思路——以氯巴占为例. 云南警官学院学报. 2024(01): 13-17 .
    2. 左玮,张波,张抒扬. 罕见病用药保障现状与挑战. 罕见病研究. 2024(02): 155-163 .
    3. 石静天,陈超阳,杨婷,魏然,张玄龄,王梓凝,胡晓娟,周颖. 氯巴占与大麻二酚辅助治疗Lennox-Gastaut综合征新进展. 罕见病研究. 2024(02): 252-259 .
    4. 陈辉艳,梁莎,王映飞,马慧,黄华驰,黄卫保. 3.0T MRI在儿童癫痫疾病的临床应用价值. 分子影像学杂志. 2024(06): 644-648 .
    5. 张玉平,许宝才,叶磊. 林钦甫老中医治疗脑病医案4则. 新中医. 2024(14): 239-242 .
    6. 涂彩霞,任丹阳,沈建玲,李云巍,杨琰茗,严爱花,李琳,李惠英. 氯巴占附加治疗儿童难治性癫痫的有效性和安全性单组率的Meta分析. 中国药房. 2024(15): 1893-1898 .
    7. 何米兰,王立和,赵国晓,李诗雅,夏勇波. Neurotrophin-3、LncRNA H19与小儿癫痫持续状态严重程度的关系及对预后预测效能研究. 疑难病杂志. 2024(10): 1210-1215 .
    8. 浙江大学 ,中国食品药品检定研究院 ,海军军医大学第二附属医院. 人工智能医疗器械性能评价通用方法专家共识(2023). 协和医学杂志. 2023(03): 494-503 . 本站查看
    9. 聂虹婷,张伊明,邓劼,傅征然,王晓玲. 基于AGREEⅡ的儿童癫痫药物治疗指南质量评价. 儿科药学杂志. 2023(07): 1-7 .
    10. 樊珂,董斌. 女性月经性癫痫的诊治进展. 医学理论与实践. 2023(13): 2196-2198+2165 .
    11. 党洋斌,梁宇欣,王天成. 进行性肌阵挛癫痫相关治疗的研究进展. 中国临床药理学与治疗学. 2023(10): 1184-1194 .
    12. 彭静,庹亚莉,李巧玲,周荣,李新林,彭惠. 基于国外药物警戒安全性自发呈报系统的氯巴占儿童不良事件数据分析. 中国药物警戒. 2023(11): 1264-1268 .
    13. 孙晓娟. 以护理为主导的慢病管理对癫痫患儿情绪、睡眠障碍等的影响. 世界睡眠医学杂志. 2023(09): 2098-2101 .
    14. 张学农,王燕燕,李莉娥,张敏,宋俐萍,易梦娟,吴先迪,游辉. 氯巴占片在中国健康成年受试者中的生物等效性研究. 医药导报. 2023(12): 1785-1790 .

    Other cited types(2)

Catalog

    Article Metrics

    Article views (4807) PDF downloads (518) Cited by(16)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close